Comparison of Magnetic Resonance Coronary Angiography (MRCA) With Coronary Computed Tomography Angiography (CTA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03768999|
Recruitment Status : Recruiting
First Posted : December 7, 2018
Last Update Posted : April 24, 2020
Magnetic resonance coronary angiography (MRCA) has its advantage in its ability to assess the coronary artery morphology without radiation or contrast media. The clinical application of MRCA is still challenging mainly because of technical limitations such as: its time-consuming image acquisition, inconsistent image quality, and low spatial resolution. Optimization of MRCA image acquisition method is in progress and compressed sensing (CS) with post-processing (de-noising) by deep learning reconstruction (DLR) is promising to solve these problems.
The lack of a consensus method to assess the coronary stenosis on MRCA is another issue. Generally, a stenosis in MRCA is observed as a signal intensity (SI) drop along the artery compared to the healthy segments. A previous study has reported from its comparison of MRCA with coronary angiography (CAG) that the SI drop of 35% in MRCA stenosis lesion corresponded to the significant stenosis in CAG. Although this SI drop phenomenon was not observed in a different study on chronic total obstruction cases. One of the hypothesized reasons is that the SI drop in MRCA is affected not only by the stenosis severity but also the plaque characteristics, which is not assessable by CAG. To investigate this hypothesis coronary CTA is needed, which is a robust modality to assess coronary stenosis and plaque characteristics. Comparison between MRCA with CTA has the potential to give better information for developing a robust method to assess MRCA.
In this study, the investigators aim to evaluate the feasibility of MRCA scanned with optimized protocol and post-processing, and to develop robust coronary artery assessment method on MRCA, by comparison with clinical coronary CTA.
|Condition or disease||Intervention/treatment|
|Magnetic Resonance Angiography||Diagnostic Test: Non-contrast magnetic resonance coronary angiography (MRCA)|
|Study Type :||Observational [Patient Registry]|
|Estimated Enrollment :||50 participants|
|Target Follow-Up Duration:||1 Day|
|Official Title:||Development of Magnetic Resonance Coronary Angiography (MRCA) Stenosis Assessment Quantification Method by Comparison With Coronary Computed Tomography Angiography (CTA)|
|Actual Study Start Date :||September 3, 2019|
|Estimated Primary Completion Date :||April 2021|
|Estimated Study Completion Date :||April 2021|
All participants in the study to receive Non-contrast magnetic resonance coronary angiography (MRCA)
Diagnostic Test: Non-contrast magnetic resonance coronary angiography (MRCA)
Scan non-contrast MRCA and compare the image with clinically scanned coronary computed tomography angiography (CTA).
- The SI drop (%) threshold that corresponds to the significant stenosis in coronary CTA. [ Time Frame: After the last participant MRI scan, up to 6 months ]MRCA signal intensity change compared to the proximal or distal segments of the coronary artery will be measured and compared with corresponding lesion of coronary CTA. The threshold of SI drop (%) which corresponds to the significant stenosis in CTA will be assessed.
- Semi-quantitative image quality assessment score for each segments in MRCA [ Time Frame: After participant's MRI scan, up to 2 weeks ]Image quality assessed by categorical numbers score ranging from 1 to 4 with higher scores indicating better image quality.
- Visible coronary length in MRCA [ Time Frame: After participant's MRI scan, up to 2 weeks ]The length of the coronary arteries in mm that is visually assessable which are compared with coronary CTA
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03768999
|Contact: Yoko Kato, MD, Ph.Dfirstname.lastname@example.org|
|Contact: Jaclyn C Sesso, BSNemail@example.com|
|United States, Maryland|
|Division of Cardiology, Johns Hopkins University School of Medicine||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Joao AC Lima, MD, PhD 410-614-1284 firstname.lastname@example.org|
|Principal Investigator:||Joao AC Lima, MD||Johns Hopkins University|